Skip to Main Content

Advertisement intended for health care professionals

Skip Nav Destination

Naveen Pemmaraju: A New Option for Myelofibrosis?

December 30, 2021

Naveen Pemmaraju, MD, discusses results from a phase I/II trial of tagraxofusp in patients with relapsed/refractory myelofibrosis, a disease with only one approved treatment option.

Advertisement intended for health care professionals

Connect with us:

CURRENT ISSUE
November 2024

Advertisement intended for health care professionals

Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals